Phase 3, multicenter, randomized, double-blind, placebo-controlled study of intravenous FDY-5301 in patients with anterior ST-segment elevation myocardial infarction. IOCYTE AMI-3
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: Faraday Pharmaceuticals, Inc.
- Phase: III
- Execution start: 17/01/2022
- End of execution: 31/08/2024
- IP: JOAQUIN SANCHEZ GILA